Do you feel that this modification was made for any other purpose tha to increase MIT's "cut" of MNTA's share of m-Lovenox's profits?
It would make no sense to just give MIT either more or less.
I would assume that the new deal slightly "de-risks" the MNTA side. So MIT will come out better IF mL stays sole generic, but MNTA saves money if tL gets approved.